Ganaplacide/ Lumefantrine

Novartis

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Potential for prophylaxis
MoA
  • Recent data suggest effect on parasite internal protein secretory pathway. Target not yet determined. Decreased susceptibility to ganaplacide is associated with mutations in three P. falciparum genes, CARL (cyclic amine resistance locus), UDP-galactose and Acetyl-CoA transporters
Key features

Ganaplacide

  • Novel mechanism of action – activity against parasites that are resistant to current drugs

  • Rapid killing of parasites (parasite clearance time <48 hours)
  • Effective against P. falciparum and P. vivax species
  • Transmission-blocking activity in a Standard Membrane Feeding Assay
  • Potential for prophylaxis 

Lumefantrine

  • New lumefantrine formulation with improved bioavailability allowing once daily administration 
Status
  • Phase llb combination studies ongoing

Next milestone
  • Phase llb study completion

Previously
  • Previous names: KAF156, GNF156. Novartis in discovery partnership with MMV, Wellcome Trust, and the Swiss Tropical and Public Health Institute
MMV Project Director
  • Dr Gonzalo Acuña